3T Biosciences

3T Biosciences is a biotechnology company developing immunotherapies that is headquartered in Menlo Park, California and was founded in 2017 by Luke Lee, Leah Sibener, and Marvin Gee.

3T Biosciences is known for work in the T-cell therapy space. The company is utilizing machine learning to identify and predict which chemicals are found on cancer cells, but not normal ones. Then the company uses a new genetic engineering process to modify T-cells. The T-cells, which are a type of white blood cell, are used to target the cancerous chemicals. This type of therapy is currently being used to combat breast, lung, and prostate cancers. The goal of the company is to raise T-cell therapies to a new standard.

Funding

Seed

On October 4, 2017 3T Biosciences completed their seed funding round with $12 million in capital from Sean Parker (lead investor), Peter Thiel, Starlight Ventures, OS Fund, Menlo Ventures, CRV, and Asset Management Ventures (AMV).